MAEA

Across TCGA pan-cancer cohorts, MAEA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAEA data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAEA mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAEA expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where MAEA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.295	0.652	.007	32	view →
HNSC	OS	Median	All	1.000	0.960	.026	5	view →
LSCC	OS	Median	II,III,IV	1.000	0.905	.021	3	view →
CCRCC	DFS	Tertile	All	0.614	1.000	.026	2	view →
GBM	DFS	Tertile	All	0.328	0.485	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAEA–PDAC (OS)

Open the PDAC breakdown →